Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEADER PAD
2024-512091-35-01Phase 3Authorised
- Sponsor
- Hamilton Health Sciences
- Start
- Jun 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised trial in arteriosclerosis obliterans comparing Colchicine with Placebo (2 arms). Primary endpoint: Major adverse cardiovascular and limb events. Planned start Jun 2025; status: authorised.
02
Drugs
colchicine
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on 2024-512091-35-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512091-35-01.